Seattle Genetics (NASDAQ: SGEN) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.
Volatility and Risk
Seattle Genetics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
This is a summary of recent ratings and price targets for Seattle Genetics and Acorda Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Seattle Genetics currently has a consensus price target of $63.71, indicating a potential upside of 14.29%. Acorda Therapeutics has a consensus price target of $21.83, indicating a potential downside of 5.89%. Given Seattle Genetics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Seattle Genetics is more favorable than Acorda Therapeutics.
Earnings and Valuation
This table compares Seattle Genetics and Acorda Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Seattle Genetics||$482.25 million||18.29||-$125.53 million||($0.88)||-63.35|
|Acorda Therapeutics||$588.29 million||1.86||-$223.35 million||$1.04||22.31|
Seattle Genetics has higher earnings, but lower revenue than Acorda Therapeutics. Seattle Genetics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Seattle Genetics and Acorda Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Seattle Genetics beats Acorda Therapeutics on 7 of the 12 factors compared between the two stocks.
About Seattle Genetics
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
About Acorda Therapeutics
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.